About Us
Cell and gene medicine can produce life-changing therapies for patients suffering from incurable diseases.
Who We Are
Foundation for Cell & Gene Medicine is dedicated to providing the education, information, and research needed to accelerate patient awareness of and access to these transformative therapies.
The Foundation for Cell & Gene Medicine is an independent, 501(c)(3) non-profit organization established in 2018 by the Alliance for Regenerative Medicine (ARM), the preeminent international advocacy organization for regenerative medicine and advanced therapies.
Our Mission
The Foundation for Cell and Gene Medicine serves as the educational and information catalyst on issues fundamental to making gene and cell therapies, tissue-engineered products and other regenerative medicine treatments available to patients.
Our Strategy
We examine, quantify, clarify and inform stakeholders about the clinical and societal benefits of these therapies. We convene to raise awareness among patients, caregivers, healthcare pros, and other stakeholders about the progress, challenges and results of cell and gene therapies. By educating, the Foundation accelerates patient access to safe, effective, transformative, and potentially curative therapies.
The programs of the Foundation for Cell & Gene Medicine educate, engage, and empower patients, caregivers, industry leaders, and other stakeholders to help increase understanding of gene therapy, gene editing, cell therapy, tissue-engineering and organ regeneration.Our educational and research projects increase public awareness of the clinical and social benefits of gene medicine to help expedite the development of life-saving therapies.
“Gene medicine will achieve its vast potential only when the public, patients, and caregivers understand and accept it as a safe and effective therapeutic option.”
— STEWART PARKER, Principal, Parker BioConsulting; Former Chair and current member of Board of Directors, Foundation for Cell and Gene Medicine
Our Programs
The Foundation for Cell & Gene Medicine conducts programs that are essential to getting treatments and cures to the patients who need them. Led by Steering Committees of leading cell and gene medicine experts, our programs are organized efforts to build education in cell and gene medicine, analyze the health and economic impact of these therapies, and determine what delivery infrastructure is required for long-term success
Our Board of Directors
Margaret Anderson
Consulting Managing Director, Deloitte Consulting LLP
Nicole Boice
Co-Founder and Executive Director, RARE-X
Sarah Creviston, MPA
Global Vice President, Patient Advocacy and Government Affairs, Novartis Gene Therapies
Amy Duross
Co-Founder and CEO, Vineti
Ellen Feigal, MD
Partner, NDA Partners, LLC
Beverley Francis-Gibson
President and CEO, Sickle Cell Disease Association of America
Pat Furlong
Founding President and CEO, Parent Project Muscular Dystrophy (PPMD)
Don Gibbons
Consultant, DLG Strategic Communication
Kathy Hudson
Former Chief of Staff and Deputy Director, National Institutes of Health
Brett Kopelan*
Executive Director, debra of America
Michael May, PhD
CEO, CCRM
Adrian McKemey, PhD*
R&D Strategy Solutions, IQVIA
Maria T. Millan, MD*
President and CEO, California Institute for Regenerative Medicine (CIRM)
David Nagler
Independent Advisor, former SVP, HR & Corporate Affairs, Audentes
Stewart Parker
Principal, Parker BioConsulting
Dennis Purcell
Founder, Senior Advisor, Aisling Partners
Brock Reeve
Executive Director, Harvard Stem Cell Institute
Martha Rook, PhD*
Chief Technical Operations Officer, Sigilon Therapeutics, Inc.
Morrie Ruffin
Managing Partner, Adjuvant Partners
Frank Sasinowski
Director, Hyman, Phelps & McNamara, PC
Bob Smith*
Senior Vice President, Global Gene Therapy, Pfizer, Inc.
David Smith
Counsel, Troutman Pepper
Phil Vanek, PhD*
Chief Technology Officer, Gamma Biosciences
Michael Werner
Health and Life Sciences Partner, Holland and Knight, LLC
Claudia Zylberberg, PhD
CEO, Akron Biotech
*Member of the Executive Committee